STAT

•

Saluran • 2 Acara

Bisnis

Bisnis

Setiap Minggu
Berita

Berita

Setiap Dua Minggu

16/12/2021

Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

We've come to our last episode of the year, and first, STAT’s Helen Branswell joins us to talk about Omicron, boosters, and the past and future of the Covid-19 pandemic. Then, we'll review the year that was in biotech, discuss the suddenly virtual J.P. Morgan Healthcare Conference, and look forward to 2022.

16/12/2021

•

35 mnt
07/11/2024

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

07/11/2024

•

39 mnt
21/05/2020

Episode 112: Moderna's scant coronavirus data and the plight of the day trader

When is a press release worth $5 billion? Can biotech stocks replace sports? And how will we know if a coronavirus vaccine actually works?

21/05/2020

•

19 mnt
24/10/2024

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

Will an activist investor campaign against Pfizer lead to big changes at the struggling Pharma giant? Why are some experts questioning the regulatory standards used to approve gene therapies for Duchenne muscular dystrophy? What’s the difference between Novo Holdings and Novo Nordisk, and will it impact a $16 billion acquisition of Catalent? And what lies ahead for Robert F. Kennedy Jr. and the Make America Healthy Again movement?

24/10/2024

•

34 mnt
02/10/2025

372: A pharma C-suite shakeup and Trump's deal with Pfizer

How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump's "most-favored nation" pricing deal with Pfizer.

02/10/2025

•

28 mnt
31/01/2019

Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

31/01/2019

•

25 mnt
18/03/2021

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain the latest data on an Alzheimer's disease treatment from Eli Lilly and why it has polarized experts in the field. Finally, we make a modest proposal to the biotech industry: Give honesty a chance.

18/03/2021

•

30 mnt
31/05/2018

Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?

Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

31/05/2018

•

23 mnt
06/12/2023

93: Rep. Raul Ruiz on going from the emergency room to Congress

Before he joined Congress, Rep. Raul Ruiz, a Democrat from California, worked in another chaotic environment: the emergency department. Today, he says, he tries to bring his background in medicine and public health to policymaking. In particular, he has turned his attention to a shortage of infectious disease physicians that threatens U.S. preparedness for the next pandemic. Our conversation was based on his recent First Opinion essay, “The infectious disease doctor shortage threatens future pandemic preparedness.” Don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

06/12/2023

•

30 mnt
31/03/2022

Introducing: Color Code

As long as there's been a medical system, it's been one that is rife with instances of mistreatment — both on the individual and community levels — that have harmful effects on how Black Americans view the health care system. In the first episode of the new STAT podcast Color Code, host Nick St. Fleur speaks with doctors, researchers, and a patient who are all trying to repair the relationship between Black people and the medical institution. You can find Color Code on any platform you use to get your podcasts. Episodes are released every other week.

31/03/2022

•

29 mnt

Voices from the frontiers of health and medicine